- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02586857
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095-1769
- Research Site
-
Palo Alto, California, United States, 94304
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Research Site
-
Boston, Massachusetts, United States, 02215
- Research Site
-
Boston, Massachusetts, United States, 2215
- Research Site
-
-
New York
-
New York, New York, United States, 10021
- Research Site
-
-
Washington
-
Vancouver, Washington, United States, 98684
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women ≥18 years of age
- Histologically confirmed GBM at first or second recurrence after concurrent or adjuvant chemotherapy or radiotherapy (must have received temozolomide).
- Radiographic demonstration of disease progression by MRI following prior therapy.
- Measurable disease (bidimensional) as defined by the RANO criteria, with a minimum measurement of 1 cm in longest diameter on MRI performed within 21 days of first dose of acalabrutinib; MRI must have been obtained ≥4 weeks after any salvage surgery after first or second relapse.
- Stable or decreasing dose of corticosteroids ≥5 days before baseline MRI (at study entry).
- On a stable dose of any required therapy (such as anticonvulsant medication for subjects to be enrolled into the Phase 1b portion), for ≥3 weeks before the first dose of acalabrutinib.
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
- Life expectancy ≥ 12 weeks.
- Completion of all prior anticancer therapy before first ACP-196 dose.
Need to have recovered (i.e., Grade ≤1 or baseline) from AEs associated with prior cancer therapy. Note: Subjects with Grade ≤2 neuropathy or Grade
- 2 alopecia are an exception, and may qualify for the study.
Exclusion Criteria:
- Three or more prior lines of systemic therapy for GBM.
- Prior malignancy (other than GBM), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥2 years. Any cases of prior malignancy allowed on study are to be approved by the study medical monitor.
- Significant cardiovascular disease.
- Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
- Evidence of bleeding diathesis or coagulopathy.
- Requires urgent palliative intervention for primary disease
- Requires treatment with a strong CYP3A4 inhibitor..
- History of stroke or clinically significant intracranial hemorrhage within 6 months before first dose of study drug.
- Breastfeeding or pregnant.
- Subjects previously treated with bevacizumab (Avastin)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
ACP-196 200 mg administered orally (PO) twice per day (BID)
|
Cohort 1: ACP-196 200 mg (PO) twice per day (BID) Cohort 2: ACP-196 400 mg (PO) once per day (QD).
Other Names:
|
Experimental: Cohort 2
ACP-196 400mg administered orally (PO) once per day (QD).
|
Cohort 1: ACP-196 200 mg (PO) twice per day (BID) Cohort 2: ACP-196 400 mg (PO) once per day (QD).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of Tumor Status for Overall Response Rate With Use of RANO Criteria.
Time Frame: On Cycle 3 Day 1, Cycle 4 Day 1 (4 weeks after Cycle 3 Day 1 scan to evaluate for response stability), then on Day 1 of every other cycle (every 8 weeks) thereafter (e.g., Cycle 6 Day 1, Cycle 8 Day 1)
|
To evaluate the efficacy of acalabrutinib monotherapy in subjects with recurrent GBM based on overall response rate (ORR) per the Response Assessment in Neuro-oncology (RANO) criteria.
Responses are either complete response (CR) or partial response (PR) by RANO.
|
On Cycle 3 Day 1, Cycle 4 Day 1 (4 weeks after Cycle 3 Day 1 scan to evaluate for response stability), then on Day 1 of every other cycle (every 8 weeks) thereafter (e.g., Cycle 6 Day 1, Cycle 8 Day 1)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Acerta Clinical Trials, 1-888-292-9613; acertamc@dlss.com
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Tyrosine Kinase Inhibitors
- Acalabrutinib
Other Study ID Numbers
- ACE-ST-209
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma Multiforme
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
University of UtahWithdrawnGlioblastoma Multiforme (GBM)United States
-
Sunnybrook Health Sciences CentreRecruitingGlioblastoma Multiforme, AdultCanada
-
Hebei Senlang Biotechnology Inc., Ltd.RecruitingGlioblastoma Multiforme, AdultChina
-
Polaris GroupRecruitingGlioblastoma Multiforme (GBM)Taiwan
-
University of IowaEisai Inc.TerminatedPrimary Glioblastoma MultiformeUnited States
Clinical Trials on ACP-196
-
Acerta Pharma BVCompletedHealthy VolunteersUnited States
-
Acerta Pharma BVMerck Sharp & Dohme LLCCompletedMetastatic Pancreatic CancerUnited States
-
Acerta Pharma BVActive, not recruitingChronic Lymphocytic LeukemiaUnited States, Italy, Spain, United Kingdom, Belgium, Denmark, Hungary, Poland, Australia, Germany, Israel, Netherlands, Turkey, France, New Zealand
-
Weill Medical College of Cornell UniversityAstraZenecaWithdrawnChronic Lymphocytic Leukemia | CLL/SLLUnited States
-
Acerta Pharma BVCompletedHepatic InsufficiencyUnited States
-
Baker Heart and Diabetes InstituteCompletedDiabetic NephropathiesAustralia
-
Kartos Therapeutics, Inc.RecruitingChronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Diffuse Large B Cell LymphomaBelgium, Korea, Republic of, United States, United Kingdom, Italy, Switzerland, Australia, France, Poland, Portugal, Czechia
-
Acerta Pharma BVActive, not recruitingWaldenström Macroglobulinemia (WM)Spain, United States, United Kingdom, France, Italy, Greece, Netherlands
-
Acerta Pharma BVCompletedHealthy VolunteersUnited States
-
Acerta Pharma BVActive, not recruitingMantle Cell Lymphoma (MCL)Belgium, France, United Kingdom, United States, Italy, Poland, Netherlands, Australia, Czechia, Spain